Target type: biologicalprocess
The process in which a relatively unspecialized thymocyte acquires specialized features of a T-helper cell. [GOC:ebc]
T-helper (Th) cell differentiation is a crucial process in adaptive immunity, enabling the immune system to mount targeted responses to specific pathogens. It involves a complex interplay of signaling pathways and transcription factors, ultimately leading to the development of distinct Th cell subsets with specialized functions.
The journey of a Th cell begins with a naive CD4+ T cell, which is initially uncommitted to any particular lineage. Upon encountering an antigen presented by an antigen-presenting cell (APC) in the context of MHC II, the naive T cell receives activation signals. These signals trigger the expression of the transcription factor STAT5, which in turn induces the production of the cytokine IL-2. IL-2 promotes the proliferation of the activated T cell, generating a pool of cells poised for further differentiation.
The fate of these activated T cells depends on the cytokine milieu they encounter. The differentiation of Th cells is primarily driven by the cytokines produced by APCs, other immune cells, and even the Th cells themselves. Different cytokine profiles lead to the development of distinct Th subsets:
* **Th1 cells:** Induced by the cytokine IL-12 produced by APCs, Th1 cells are key players in cellular immunity. They produce IFN-γ, which activates macrophages and promotes the killing of intracellular pathogens.
* **Th2 cells:** Differentiation of Th2 cells is driven by IL-4, a cytokine secreted by mast cells and basophils. Th2 cells are essential for humoral immunity, producing IL-4, IL-5, and IL-13, which stimulate antibody production by B cells and promote allergic responses.
* **Th17 cells:** Differentiation of Th17 cells is triggered by IL-6, IL-21, and TGF-β, produced by various immune cells. Th17 cells play a critical role in host defense against extracellular bacteria and fungi, secreting IL-17 and IL-22, which induce inflammation and recruit neutrophils.
* **T follicular helper (Tfh) cells:** Tfh cells are characterized by the expression of the transcription factor Bcl6 and the production of IL-21. They reside in germinal centers of lymph nodes and provide help to B cells for antibody production.
* **Regulatory T cells (Tregs):** Tregs develop in the thymus or peripherally under the influence of TGF-β and IL-2. They suppress immune responses and maintain tolerance to self-antigens, preventing autoimmune diseases.
The differentiation of Th cells is a tightly regulated process, involving intricate feedback loops between cytokines, transcription factors, and signaling pathways. Different cytokines can influence the expression of specific transcription factors, which in turn control the production of cytokines, creating a dynamic interplay that determines the ultimate fate of the Th cell.
In summary, T-helper cell differentiation is a complex and multifaceted process that plays a crucial role in adaptive immunity. The development of distinct Th subsets, each with specific functions, allows the immune system to mount tailored responses to diverse pathogens and maintain immune homeostasis.'
"
Protein | Definition | Taxonomy |
---|---|---|
Prostaglandin E2 receptor EP4 subtype | [no definition available] | Canis lupus familiaris (dog) |
Prostaglandin E2 receptor EP4 subtype | A prostaglandin E2 receptor EP4 subtype that is encoded in the genome of human. [PRO:WCB, UniProtKB:P35408] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
metergoline | metergoline : An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7. Metergoline: A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy. | carbamate ester; ergoline alkaloid | dopamine agonist; geroprotector; serotonergic antagonist |
ah 6809 | 6-isopropoxy-9-oxoxanthene-2-carboxylic acid: structure given in UD | xanthones | |
dinoprostone | prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. | prostaglandins E | human metabolite; mouse metabolite; oxytocic |
dinoprost | Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor. | monocarboxylic acid; prostaglandins Falpha | human metabolite; mouse metabolite |
butaprost | |||
cloprostenol | Cloprostenol: A synthetic prostaglandin F2alpha analog. The compound has luteolytic effects and is used for the synchronization of estrus in cattle. | prostanoid | |
tg4-155 | TG4-155: an EP2 receptor antagonist; structure in first source | ||
mk-0524 | MK-0524: a potent orally active human prostaglandin D(2) receptor 1 antagonist; structure in first source | indolyl carboxylic acid | |
cp533536 | CP533536: an EP2 receptor-selective prostaglandin E2 agonist that induces bone healing; structure in first source | monocarboxylic acid | |
amg 009 | AMG 009: an anti-inflammatory agent; structure in first source | ||
dg 041 | |||
cj-042794 | aromatic ether | ||
gw9508 | GW9508: structure in first source | aromatic amine | |
cj-023,423 | grapiprant: a potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties; cyclooxygenase inhibitors | ||
l-798106 | L-798106 : An N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of o-naphthalen-2-ylcinnamic acid with the sulfonamide group of 5-bromo-2-methoxybenzenesulfonamide. It is a selective antagonist for the prostanoid receptor EP3, a prostaglandin receptor for prostaglandin E2 (PGE2). | aromatic ether; bromobenzenes; N-sulfonylcarboxamide | prostaglandin receptor antagonist |
cp 544326 | CP 544326: structure in first source | ||
fevipiprant | fevipiprant: a CRTh2 antagonist; structure in first source | ||
fr181157 | |||
pf-04418948 | 1-(4-fluorobenzoyl)-3-(((6-methoxy-2-naphthyl)oxy)methyl)azetidine-3-carboxylic acid: structure in first source | ||
cay 10580 | 2-(3-hydroxyoctyl)-5-oxo-1-pyrrolidineheptanoic acid : A pyrrolidin-2-one substituted by 6-carboxyhexyl and 3-hydroxyoctyl groups at positions 1 and 2, respectively. It is a potent prostaglandin EP4 receptor agonist (Ki=35 nM). CAY 10580: a E-prostanoid EP4 receptor agonist | hydroxy monocarboxylic acid; pyrrolidin-2-ones; secondary alcohol | prostaglandin receptor agonist |
tg6-10-1 | TG6-10-1: brain-permeant prostaglandin E receptor 2 antagonist; structure in first source |